Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease

Neuroscience Letters

Volumn 288, Issue 1, 2000, Pages 21-24

  Bhojak, Tejal J ^a   Dekosky, Steven T ^a,b   Ganguli, Mary ^b   Kamboh, M Ilyas ^a,b  

^a GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; Cathepsin D; Interleukin 6; Polymorphism

Indexed keywords

APOLIPOPROTEIN E4; ASPARTIC PROTEINASE; CATHEPSIN D; INTERLEUKIN 6;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CATHEPSIN D; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 0034617348     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01185-X     Document Type: Article

References (24)

1. 2 macroglobulin influences the risk for Alzheimer's disease. Ann. Neurol. 47:2000;138-139.
2. Bagli M., Papassotiropoulos A., Knapp M., Jessen F., Rao M.L., Maier W., Heun R. Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population. Neurosci. Lett. 283:2000;109-112.
3. Bauer J., Ganter S., Strauss S., Stadtmuller G., Frommberger U., Bauer H., Volk B., Berger M. The participation of interleukin-6 in the pathogenesis of Alzheimer's disease. Res. Immunol. 143:1992;650-657.
4. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202:1995;17-20.
5. Bowcock A., Ray A., Erlich H., Sehgal P. Rapid detection and sequencing of alleles in the 3' region of the interleukin-6 gene. Nucl. Acids Res. 17:1989;6855-6864.
6. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B.A., Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6. Proc. Natl. Acad. Sci., USA. 40:1993;10061-10065.
7. Chevallier N., Vizzavona J., Marambaud P., Baur C.P., Spillantini M., Fulcrand P., Martinez J., Goedert M., Vincent J.P., Checler F. Cathepsin D displays in-vitro β-secretase-like specificity. Brain Res. 750:1997;11-19.
8. Citron M., Teplow D.B., Selkoe D.J. Generation of amyloid beta protein from its precursor is sequence- specific. Neuron. 14:1995;661-670.
9. Evin G., Cappai R., Li Q.X., Culvenor J.G., Small D.H., Beyreuther K., Masters C.L. Candidate γ-secretases in the generation of the carboxyl terminus of the Alzheimer's disease βA4 amyloid: possible involvement of cathepsin D. Biochemistry. 34:1995;14185-14192.
10. Farrer L.A., Cupples L.A., Haines J.I., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijin C.M. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer's disease. (For the Alzheimer's Disease Meta Analysis Consortium). J. Am. Med. Assoc. 278:1997;1345-1356.
11. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. The effect of novel polymorphisms on interleukin-6 (IL-6) gene transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102:1998;1369-1376.
12. Kamboh M.I., Aston C.E., Hamman R.F. The relationship of the APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. Atherosclerosis. 112:1995;145-159.
13. Kamboh M.I., Sanghera D.K., Ferrell R., DeKosky S.T. APOE*4- associated Alzheimer's disease risk is modified by α-1 antichymotrypsin polymorphism. Nat. Genet. 10:1995;486-488.
14. Lendon C.L., Ashall F., Goate A. Exploring the etiology of Alzheimer's disease using molecular genetics. J. Am. Med. Assoc. 277:1997;825-831.
15. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory drugs as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
16. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ARDA workgroup under the auspices of Department of Health and Human Service Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
17. McIlroy S.P., Dynan K.B., McGleenon B.M., Lawson J.T., Passmore A.P. Cathepsin D gene exon 2 polymorphism and sporadic Alzheimer's disease. Neurosci. Lett. 273:1999;140-141.
18. Murray R.E., McGuigan F., Grant S.F., Reid D.M., Ralston S.H. Polymorphisms in the interleukin-6gene are associated with bone mineral density. Bone. 21:1997;89-92.
19. Papassotiropoulos A., Bagli M., Feder O., Jessen F., Maier W., Rao M.L., Ludwig M., Schwab S.G., Heun R. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease. Neurosci. Lett. 262:1999;171-174.
20. Papassotiropoulos A., Bagli M., Jessen F., Bayer T.A., Maier W., Rao M.L., Heun R. A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann. Neurol. 45:1999;666-668.
21. Papassotiropoulos A., Bagli M., Kurz A., Kornhuber J., Forstl H., Maier W., Pauls J., Lautenschlager N., Heun R. A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann. Neurol. 47:2000;399-403.
22. Touitou I., Capony F., Brouillet J., Rochefort H. Missesnse polymorphism (C/T224) in the human cathepsin D pro-fragment determined by polymerase chain reaction- single stranded conformational polymorphism analysis and possible consequences of in cancer cells. Eur. J. Cancer. 3:1994;390-394.
23. Van Duijn C.M., Hofman A., Nagelkerken L. Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease. Neurosci. Lett. 108:1990;350-354.
24. Vassar R., Bennett B., Safura B., Kahn S., Mendiaz E., Denis P., Teplow D., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M., Biere A.L., Curran E., Burgess T., Louis J.L., Collins F., Treanor J., Rogers G., Citron M. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 286:1999;735-741.